Director at LENZ Therapeutics (NASDAQ: LENZ) receives 22,100 options

Rhea-AI Filing Summary

LENZ Therapeutics director Frederic Guerard received a grant of stock options for 22,100 shares of common stock. The options have an exercise price of $6.63 per share and expire on June 15, 2036. Following this grant, Guerard holds 22,100 derivative securities directly.

According to the vesting terms, all 22,100 options vest 100% on the earlier of June 15, 2027 or the date of the next annual meeting of stockholders, as long as he continues to serve as an Outside Director under the company’s Outside Director Compensation Policy.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Guerard Frederic

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	22,100	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 22,100 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 22,100 options Exercise price: $6.63 per share Post-transaction derivative holdings: 22,100 derivative securities +2 more

5 metrics

Options granted 22,100 options Stock Option (right to buy) grant to director

Exercise price $6.63 per share Conversion or exercise price of options

Post-transaction derivative holdings 22,100 derivative securities Total options held following grant

Vesting date trigger June 15, 2027 Full vesting or earlier next annual stockholder meeting

Expiration date June 15, 2036 Option contract expiration

Key Terms

Stock Option (right to buy), Outside Director, Outside Director Compensation Policy, annual meeting of stockholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Outside Director financial

"Subject to the Reporting Person continuing to be an Outside Director"

Outside Director Compensation Policy financial

"as defined in the Issuer's Outside Director Compensation Policy"

annual meeting of stockholders financial

"the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders"

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guerard Frederic

(Last) (First) (Middle)

C/O LENZ THERAPEUTICS, INC.

201 LOMAS SANTA FE DRIVE, SUITE 300

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LENZ Therapeutics, Inc. [ LENZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.63	06/15/2026		A		22,100		(1)	06/15/2036	Common Stock	22,100	$0	22,100	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.

Remarks:

	/s/ Daniel R. Chevallard, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did LENZ director Frederic Guerard report on this Form 4?

Frederic Guerard reported receiving a grant of 22,100 stock options for LENZ Therapeutics common shares. These derivative securities were awarded as compensation, not purchased on the open market, and give him the right to buy shares at a fixed exercise price in the future.

What is the exercise price and size of the LENZ stock options granted to Frederic Guerard?

The grant covers 22,100 stock options with an exercise price of $6.63 per share. This price is the amount he would pay per share if he chooses to exercise the options, giving clear terms for potential future share acquisition.

When do Frederic Guerard’s LENZ Therapeutics stock options vest?

All 22,100 options vest 100% on the earlier of June 15, 2027 or the date of the next annual meeting of stockholders. Vesting is conditioned on Guerard continuing to serve as an Outside Director under the company’s Outside Director Compensation Policy.

What is the expiration date of the LENZ stock options granted to Frederic Guerard?

The stock options granted to Frederic Guerard expire on June 15, 2036. After this expiration date, any unexercised options become worthless, so potential future share purchases must occur before that long-dated deadline if he chooses to exercise.

Is Frederic Guerard’s LENZ Form 4 transaction a stock purchase or a compensation award?

The Form 4 reflects a compensation-related award, not an open-market stock purchase. The transaction is coded as a grant or award acquisition of derivative securities, providing Guerard with options to buy shares rather than immediate ownership of common stock.

How many LENZ derivative securities does Frederic Guerard hold after this option grant?

After the reported transaction, Guerard holds 22,100 derivative securities directly. These correspond to stock options giving the right to acquire 22,100 shares of LENZ Therapeutics common stock if he exercises them under the specified terms and vesting schedule.